- Mar 09, 2023 Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
- Mar 01, 2023 Foghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference
- Jan 09, 2023 Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023
- Dec 05, 2022 Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting
- Nov 22, 2022 Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference
- Nov 14, 2022 Foghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting
- Nov 09, 2022 Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting
- Nov 08, 2022 Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update
- Oct 27, 2022 Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors
- Oct 26, 2022 Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program
Displaying 41 - 50 of 93